Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.761 USD | +0.78% |
|
-1.17% | +2.84% |
05-03 | Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
05-03 | Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 440 | 47.45 | 31.38 | 32.62 | - | - |
Enterprise Value (EV) 1 | 246.5 | -61.19 | -60.67 | -21.84 | -14.84 | -9.363 |
P/E ratio | -2.7 x | -0.79 x | -0.61 x | -0.7 x | -0.76 x | -1.27 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 18.9 x | 2.77 x | 1.39 x | 1.21 x | 0.88 x | 0.64 x |
EV / Revenue | 10.6 x | -3.57 x | -2.69 x | -0.81 x | -0.4 x | -0.18 x |
EV / EBITDA | -5.39 x | 1.01 x | 1.13 x | 0.46 x | 0.34 x | 0.26 x |
EV / FCF | -4,236,673 x | 937,315 x | - | - | - | - |
FCF Yield | -0% | 0% | - | - | - | - |
Price to Book | 2 x | 0.29 x | 0.27 x | 0.37 x | 0.69 x | 1.12 x |
Nbr of stocks (in thousands) | 41,353 | 41,994 | 42,409 | 42,862 | - | - |
Reference price 2 | 10.64 | 1.130 | 0.7400 | 0.7610 | 0.7610 | 0.7610 |
Announcement Date | 04/03/22 | 03/03/23 | 01/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 23.23 | 17.13 | 22.52 | 27.07 | 37.06 | 50.79 |
EBITDA 1 | - | -45.7 | -60.38 | -53.46 | -47.65 | -43.04 | -36.67 |
EBIT 1 | - | -47.23 | -63.22 | -56.56 | -50.6 | -46.17 | -40.08 |
Operating Margin | - | -203.31% | -368.99% | -251.18% | -186.94% | -124.59% | -78.92% |
Earnings before Tax (EBT) 1 | - | - | -61.38 | - | -47.1 | -44.7 | - |
Net income 1 | -42.54 | -78.03 | -60.81 | -52.47 | -46.79 | -43.57 | -38.37 |
Net margin | - | -335.88% | -354.91% | -232.99% | -172.87% | -117.57% | -75.55% |
EPS 2 | -23.72 | -3.940 | -1.430 | -1.220 | -1.087 | -1.007 | -0.6000 |
Free Cash Flow | - | -58.18 | -65.29 | - | - | - | - |
FCF margin | - | -250.43% | -381.06% | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 22/03/21 | 04/03/22 | 03/03/23 | 01/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 5.208 | 4.16 | 3.86 | 4.739 | 4.374 | 5.035 | 5.002 | 6.145 | 6.337 | 5.611 | 6 | 7.05 | 8.35 | - | - |
EBITDA 1 | -14.11 | -14.44 | -13.39 | -16.15 | -16.4 | -14.11 | -14.28 | -13.67 | -11.39 | -13.47 | -12.5 | -11.3 | -10.9 | - | - |
EBIT 1 | -14.56 | -15 | -14.07 | -16.89 | -17.26 | -14.87 | -15.05 | -14.45 | -12.19 | -14.27 | -13.2 | -12 | -11.6 | - | - |
Operating Margin | -279.49% | -360.55% | -364.61% | -356.32% | -394.6% | -295.37% | -300.96% | -235.13% | -192.33% | -254.38% | -220% | -170.21% | -138.92% | - | - |
Earnings before Tax (EBT) 1 | - | -14.91 | -13.7 | -16.33 | -16.44 | -13.88 | - | - | - | -13.32 | -12.2 | -11 | -10.6 | - | - |
Net income 1 | -14.6 | -14.93 | -13.09 | -16.34 | -16.45 | -13.89 | -14.02 | -13.39 | -11.17 | -13.32 | -12.2 | -11 | -10.6 | - | - |
Net margin | -280.43% | -358.89% | -339.12% | -344.78% | -376.02% | -275.81% | -280.21% | -217.93% | -176.3% | -237.43% | -203.33% | -156.03% | -126.95% | - | - |
EPS 2 | -0.3500 | -0.3500 | -0.3100 | -0.3800 | -0.3900 | -0.3200 | -0.3300 | -0.3100 | -0.2600 | -0.3100 | -0.2767 | -0.2567 | -0.2467 | -0.2700 | -0.2400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 04/03/22 | 10/05/22 | 12/08/22 | 10/11/22 | 03/03/23 | 05/05/23 | 04/08/23 | 03/11/23 | 01/03/24 | 03/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 193 | 109 | 92.1 | 54.5 | 47.5 | 42 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -58.2 | -65.3 | - | - | - | - |
ROE (net income / shareholders' equity) | - | -156% | -31.6% | -37.2% | -47.7% | -64.2% | -73.9% |
ROA (Net income/ Total Assets) | - | - | -28.2% | - | - | - | - |
Assets 1 | - | - | 215.9 | - | - | - | - |
Book Value Per Share 2 | - | 5.330 | 3.900 | 2.740 | 2.070 | 1.100 | 0.6800 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | 3.22 | 6.74 | - | - | - | - |
Capex / Sales | - | 13.85% | 39.34% | - | - | - | - |
Announcement Date | 22/03/21 | 04/03/22 | 03/03/23 | 01/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.84% | 32.62M | |
+55.19% | 815B | |
+45.45% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+10.18% | 302B | |
+18.26% | 247B | |
+2.41% | 229B | |
+13.31% | 219B | |
+10.86% | 171B |
- Stock Market
- Equities
- RPID Stock
- Financials Rapid Micro Biosystems, Inc.